Related Experiment Video
Updated: Jul 8, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Therapeutic potential of CB2 targeting in multiple sclerosis
Fabian Docagne1, Leyre Mestre, Frida Loría
1Grupo de Neuroinmunología, Instituto Ramón y Cajal, CSIC-Avda Dr Arce, 37, 28002 Madrid, Spain. docagne@cajal.csic.es
Expert Opinion on Therapeutic Targets
|January 23, 2008
Summary
Targeting the CB2 receptor offers a promising, non-psychoactive therapeutic strategy for multiple sclerosis (MS). This review explores how CB2 activation may combat MS by reducing inflammation and promoting neuroprotection and remyelination.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Cannabinoids show therapeutic potential in multiple sclerosis (MS) animal models.
- Psychoactivity limits clinical use of traditional cannabinoids.
- The CB2 receptor offers a non-psychoactive target for MS therapy.
Purpose of the Study:
- To review mechanisms of CB2 receptor activation for therapeutic benefits in MS.
- To focus on CB2's effects on inflammation, autoimmunity, remyelination, and neuroprotection.
Main Methods:
- Literature review of preclinical and clinical studies on CB2 agonists in MS.
- Analysis of molecular and cellular pathways involved in CB2 signaling.
- Evaluation of potential therapeutic effects and limitations.
Main Results:
- CB2 activation may modulate neuroinflammation and autoimmune responses in MS.
- Evidence suggests CB2 agonists could promote remyelination and offer neuroprotection.
- Glial cells play a crucial role in mediating CB2-induced therapeutic effects.
Conclusions:
- CB2 receptor agonists represent a potential non-psychoactive treatment for MS.
- Therapeutic benefits are linked to modulation of glial cell activity.
- Potential secondary effects require careful consideration for clinical application.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...